OnabotulinumtoxinA at 195 UI may be effective in reducing the number of headaches per month and medication intake in patients with chronic migraine and medication overuse.
Treatment with fremanezumab may help reduce medication overuse and the number of days of acute medication use in individuals with chronic migraine.
Polypharmacy in individuals with primary headache may arise out of a prescribing cascade.
A period of observation after an educational session may be important to confirm medication-overuse headache (MOH) diagnoses.
Factors that were associated with medication overuse headache in this study included high headache-related disability, attempts to escape and avoid stimuli associated with pain, and the use of combination medications.
The prevalence of probable medication overuse may be high in elderly patients with migraine, and higher frequency of migraine may be associated with early onset in this patient population.
In patients with medication overuse headaches, bridge therapy with intravenous methylprednisone and diazepam was shown to reduce headache pain and painkiller intake up to 3 months after withdrawal.
In patients with chronic migraine and medication overuse, patients who frequently relapse into overuse following withdrawal have a worse clinical and psychological profile than patients who relapse less frequently.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds